GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » TFF Pharmaceuticals Inc (NAS:TFFP) » Definitions » Liabilities-to-Assets

TFFP (TFF Pharmaceuticals) Liabilities-to-Assets : 0.56 (As of Sep. 2024)


View and export this data going back to 2019. Start your Free Trial

What is TFF Pharmaceuticals Liabilities-to-Assets?

Liabilities-to-Assets is a solvency ratio indicating how much of the company’s assets are made of liabilities, calculated as total liabilities divided by total asset. TFF Pharmaceuticals's Total Liabilities for the quarter that ended in Sep. 2024 was $3.94 Mil. TFF Pharmaceuticals's Total Assets for the quarter that ended in Sep. 2024 was $7.08 Mil. Therefore, TFF Pharmaceuticals's Liabilities-to-Assets Ratio for the quarter that ended in Sep. 2024 was 0.56.


TFF Pharmaceuticals Liabilities-to-Assets Historical Data

The historical data trend for TFF Pharmaceuticals's Liabilities-to-Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

TFF Pharmaceuticals Liabilities-to-Assets Chart

TFF Pharmaceuticals Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Liabilities-to-Assets
Get a 7-Day Free Trial 0.05 0.03 0.05 0.05 0.21

TFF Pharmaceuticals Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Liabilities-to-Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.08 0.21 0.42 0.38 0.56

Competitive Comparison of TFF Pharmaceuticals's Liabilities-to-Assets

For the Biotechnology subindustry, TFF Pharmaceuticals's Liabilities-to-Assets, along with its competitors' market caps and Liabilities-to-Assets data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


TFF Pharmaceuticals's Liabilities-to-Assets Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, TFF Pharmaceuticals's Liabilities-to-Assets distribution charts can be found below:

* The bar in red indicates where TFF Pharmaceuticals's Liabilities-to-Assets falls into.


;
;

TFF Pharmaceuticals Liabilities-to-Assets Calculation

Liabilities-to-Assets ratio measures the portion of the total liabilities to the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Liabilities-to-Assets ratio is calculated by dividing total liabilities by total asset.

TFF Pharmaceuticals's Liabilities-to-Assets Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Liabilities-to-Assets (A: Dec. 2023 )=Total Liabilities/Total Assets
=2.46/12.027
=0.20

TFF Pharmaceuticals's Liabilities-to-Assets Ratio for the quarter that ended in Sep. 2024 is calculated as

Liabilities-to-Assets (Q: Sep. 2024 )=Total Liabilities/Total Assets
=3.941/7.078
=0.56

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


TFF Pharmaceuticals  (NAS:TFFP) Liabilities-to-Assets Explanation

Liabilities-to-Assets is a solvency ratio indicating how much of the company’s assets are made of liabilities. It can vary greatly across different industries, as they have different capital structure. A high Liabilities-to-Assets ratio (more leveraged) suggests that the company might have potential solvency problems, or even a signal of financial distress. Conversely, a low Liabilities-to-Assets ratio usually indicates a healthy financial situation. However, it may also suggest that the company is not expanding or not making good use of debt.


TFF Pharmaceuticals Liabilities-to-Assets Related Terms

Thank you for viewing the detailed overview of TFF Pharmaceuticals's Liabilities-to-Assets provided by GuruFocus.com. Please click on the following links to see related term pages.


TFF Pharmaceuticals Business Description

Traded in Other Exchanges
N/A
Address
1751 River Run, Suite 400, Fort Worth, TX, USA, 76107
TFF Pharmaceuticals Inc is a biopharmaceutical company focused on developing and commercializing drug products based on its patented Thin Film Freezing, or TFF, technology platform. It is focused on the development of inhaled dry powder drugs for the treatment of lung disorders.
Executives
Carlson Capital L P 10 percent owner 2100 MCKINNEY AVE, STE 1900, DALLAS TX 75201
Clint Duane Carlson 10 percent owner 2100 MCKINNEY AVENUE, SUITE 1800, DALLAS TX 75201
Zamaneh Mikhak officer: Chief Medical Officer 1751 RIVER RUN, SUITE 400, C/O TFF PHARMACEUTICALS, INC., FORT WORTH TX 76107
Robert S Mills director 8 MISTY BROOK LANE, NEW FAIRFIELD CT 06812
Kirk Allen Coleman officer: CFO, Secretary, and Treasurer 2600 VIA FORTUNA, SUITE 360, AUSTIN TX 78746
Stephen Rocamboli director C/OPARMOUNT CAPITAL, 787 SEVENTH AVE 48TH FL, NEW YORK NY 10019
Asgard Investment Corp. Ii 10 percent owner 2100 MCKINNEY AVENUE, SUITE 1800, DALLAS TX 75201
Double Black Diamond Offshore Ltd 10 percent owner CITCO FUND SERVICES, 89 NEXUS WAY, P.O. BOX 31106, CAMANA BAY E9 KY-1205
Harlan F Weisman director C/O CORONADO BIOSCIENCES, INC., 15 NEW ENGLAND EXECUTIVE PARK, BURLINGTON MA 01803
Brandi Roberts director 12390 EL CAMINO REAL #150, SAN DIEGO CA 92130
Fletcher Aaron G.l. director 40 GUEST STREET, BOSTON MA 02135
Randy H Thurman director 222 MERCHANDISE MART PLAZA, SUITE 2024, CHICAGO IL 60654
Glenn R. Mattes director, officer: President and CEO 200 ROUTE 31 NORTH, SUITE 104, FLEMINGTON NJ 08822
Malcolm Fairbairn director C/O ASCEND CAPITAL, LLC, 4 ORINDA WAY, SUITE 200-C, ORINDA CA 94563
Lung Therapeutics, Inc. 10 percent owner P.O. BOX 150183, AUSTIN TX 78715